Zymeworks Inc. (ZYME)

Healthcare

Actionable

Fundamental: 3
Sentiment: 3
Technical: 4

Bullish pullback plan: ZYME has reclaimed the 20/50/200-day and 9/21-day averages, so the preferred entry is a buy-limit near 23.60 support/EMA21 rather than a chase under 24.76 resistance; use 22.97 as the structural stop and 25.66/27.21 as targets.

Analysis as of 2026-08-11· more than 2 trading days ago

Company overview

Zymeworks Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing biotherapeutics for cancer treatment. Its lead candidates include zanidatamab, a bispecific antibody in Phase 1 and 2 trials, and ZW49, an antibody-drug conjugate in Phase 1 trials. The company collaborates with several major pharmaceutical firms and has multiple strategic partnerships and licensing agreements.

Fundamental

fair

Fundamental3

Mixed fundamentals

Zymeworks shows strong liquidity but remains unprofitable with high execution risk.

Liquidity looks strong (8-K: $403.8M cash/marketable securities at 2026-03-31), but ZYME is still unprofitable with volatile, milestone-driven revenue and material clinical/partner risks disclosed in SEC filings. Fundamental score: 3/5.

Sentiment

fair

Sentiment3

Neutral sentiment

Sentiment is neutral with limited media coverage and sparse retail engagement.

Near-term narrative is driven by post-Q2 results digestion (earnings, announced) and the still-unresolved Theravance acquisition process (ongoing_process, announced), with a modest bullish overlay from a recent price-target raise. Quantified media-sentiment delta is indeterminate (sentiment scanner returned 0 usable in-window items after a timeout); legal screen shows no regulator-confirmed investigations (only law-firm solicitation noise).

Technical

good

Technical4

Bullish recovery

Technical indicators show a bullish recovery above key moving averages.

Bullish repair with one composite weakness. Price has reclaimed the SMA20, SMA50, SMA200, EMA9, EMA21, and daily VWAP, liquidity is strong, RSI is back above 50, and MACD histogram has turned positive. The weak point is that the recovery is still in repair mode rather than full trend confirmation: EMA9 remains below EMA21 and MACD is still below zero, with resistance still sitting at 24.76.

You’re looking at 2026-08-11 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Start free

More Healthcare

Back to all stocks

Not financial advice. For informational and educational purposes only.